Percutaneous management of cholangiocarcinoma

Sep 13, 2019 by in ONCOLOGY Comments Off on Percutaneous management of cholangiocarcinoma

Key points • In general, the higher the cholangiocarcinoma (type 3 and type 4) and the more multifocal the disease/obstruction, the more likely the patient is to require percutaneous therapy/drainage…

read more

Percutaneous management of renal tumors

Sep 13, 2019 by in ONCOLOGY Comments Off on Percutaneous management of renal tumors

Key points • Imaging plays an important role in diagnosis • Thermal ablation is becoming a treatment option for select patients with small tumors • techniques include radiofrequency and cryoablation…

read more

Principles of percutaneous ablative therapies

Sep 13, 2019 by in ONCOLOGY Comments Off on Principles of percutaneous ablative therapies

Key points • Percutaneous image-guided tumor ablation uses the cytotoxic properties of thermal energy or electric field strength to cause cell death. • The thermal ablative effect due to coagulation…

read more

Surgical management of hepatic metastases

Sep 13, 2019 by in ONCOLOGY Comments Off on Surgical management of hepatic metastases

Key points • Precise assessment of disease progression and adequate selection of initial therapeutic options should be performed through a multidisciplinary approach in the treatment of liver metastases. • Selected…

read more

Gastroenteropancreatic neuroendocrine tumors

Sep 13, 2019 by in ONCOLOGY Comments Off on Gastroenteropancreatic neuroendocrine tumors

Key points • Incidence and prevalence of GEP-NET is increasing. • Recently approved systemic targeted therapeutic agents and local therapies have rekindled interest in NET management. • Multidisciplinary centers employing…

read more

Surgical management of hepatocellular carcinoma

Sep 13, 2019 by in ONCOLOGY Comments Off on Surgical management of hepatocellular carcinoma

Key points • Patients with cirrhosis are at highest risk of developing hepatocellular carcinoma (HCC) and screening with sonography every 6 months is recommended. • Early-stage HCC should be treated…

read more
Get Clinical Tree app for offline access